| Dr Franz E Schneider, MD | |
|
4801 Mcmahon Blvd Nw Ste 245, Albuquerque, NM 87114-5478 | |
| (505) 727-7833 | |
| (505) 727-9590 |
| Full Name | Dr Franz E Schneider |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 39 Years |
| Location | 4801 Mcmahon Blvd Nw Ste 245, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093708539 | NPI | - | NPPES |
| 123561603 | Medicaid | TX | |
| 930066735 | Other | TX | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | J2784 (Texas) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | MD2023-1358 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Houston Methodist St John Hospital | Nassau bay, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tmh Physician Associates Pllc | 4486711744 | 1557 |
News Archive
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.
Humans are getting older and older, and the number of people with dementia is increasing. The factors controlling degeneration of the brain are still mostly unknown. However, researchers assume that factors such as stress, accumulation of toxic waste products as well as inflammation accelerate aging. But, vice versa, there are also mechanisms that can - like a bodyguard - protect the brain from degenerating, or repair defective structures.
EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.
› Verified 8 days ago
| Entity Name | Tmh Physician Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275779225 PECOS PAC ID: 4486711744 Enrollment ID: O20090401000100 |
News Archive
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.
Humans are getting older and older, and the number of people with dementia is increasing. The factors controlling degeneration of the brain are still mostly unknown. However, researchers assume that factors such as stress, accumulation of toxic waste products as well as inflammation accelerate aging. But, vice versa, there are also mechanisms that can - like a bodyguard - protect the brain from degenerating, or repair defective structures.
EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Franz E Schneider, MD 444 Fm 1959 Rd, Ste A, Houston, TX 77034-5416 Ph: (281) 481-9400 | Dr Franz E Schneider, MD 4801 Mcmahon Blvd Nw Ste 245, Albuquerque, NM 87114-5478 Ph: (505) 727-7833 |
News Archive
The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.
Humans are getting older and older, and the number of people with dementia is increasing. The factors controlling degeneration of the brain are still mostly unknown. However, researchers assume that factors such as stress, accumulation of toxic waste products as well as inflammation accelerate aging. But, vice versa, there are also mechanisms that can - like a bodyguard - protect the brain from degenerating, or repair defective structures.
EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.
› Verified 8 days ago
Dr. Alberto Aguayo Rico, M.D, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |